Efficacy and toxicity of gemcitabine plus docetaxel combination as a second line therapy for patients with advanced stage soft tissue sarcoma

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 2, 2012, Pages 463-467

  Kaya, Ali Osman ^a   Büyükberber, Süleyman ^b   Ozkan, Metin ^c   Alkiş, Necati ^d   Sevinc, Alper ^e   Ozdemir, Nuriye Yildirim ^f   Alici, Suleyman ^g   Esbah, Onur ^d   Berk, Veli ^c   Camci, Celalettin ^e   Ulas, Arife ^d   Coskun, Uǧur ^b   Benekli, Mustafa ^b  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY   (Turkey)

^c ERCIYES UNIVERSITY   (Turkey)

^d ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^e GAZIANTEP UNIVERSITY   (Turkey)

^f ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^g MEDICAL PARK HOSPITAL   (Turkey)

Author keywords

Advanced soft tissue sarcoma; Docetaxel; Gemcitabine; Second line therapy; Turkey

Indexed keywords

ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; TAXOID;

ADULT; AGED; ARTICLE; BONE TUMOR; CANCER GRADING; DRUG EFFECT; DRUG RESISTANCE; FEMALE; FOLLOW UP; HUMAN; LIVER TUMOR; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SALVAGE THERAPY; SARCOMA; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SARCOMA; SURVIVAL RATE; TAXOIDS; YOUNG ADULT;

EID: 84873572014     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.2.459     Document Type: Article

References (19)

1. Bay JO, Ray-Coquard I, Fayette J, et al; Groupe Sarcome Français (2006). Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer, 119, 706-11.
2. Edmonson JH, Ryan LM, Blum RH, et al (1993). Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol, 11, 1269-75.
3. Hartmann JT, Oechsle K, Huober J, et al (2006). An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs, 24, 249-53.
4. '-difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res, 48, 4024-31.
5. Hensley ML, Blessing JA, Degeest K, et al (2008). Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol, 109, 323-8.
6. Hensley ML, Maki R, Venkatraman E, et al (2002). Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol, 20,2824-31.
7. Iwasaki H, Huang P, Keating MJ, Plunkett W (1997). Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood, 90, 270-8.
8. Jemal A, Siegel R, Ward E, et al (2006). Cancer statistics, 2006. CA Cancer J Clin, 56, 106-30.
9. Le Cesne A, Judson I, Crowther D, et al (2000). Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 18, 2676-84.
10. Leu KM, Ostruszka LJ, Shewach D, et al (2004). Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol, 22, 1706-12.
11. Maki RG (2007). Gemcitabine and docetaxel in metastaticsarcoma: past, present, and future. Oncologist, 12, 999-1006.
12. Maki RG, Wathen JK, Patel SR, et al (2007). Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol, 25, 2755-63.
13. Maurel J, López-Pousa A, de Las Peñas R, et al (2009). Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol, 27, 1893-8.
14. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG (1992). Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol, 19, 646-62.
15. Santoro A, Tursz T, Mouridsen H, et al (1995). Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol, 13, 1537-45.
16. Schiff PB, Fant J, Horwitz SB (1979). Promotion of microtubule assembly in vitro by taxol. Nature, 277, 665-7.
17. Schütte J, Mouridsen HT, Stewart W, et al (1990). Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer, 26, 558-61.
18. van Hoesel QG, Verweij J, Catimel G, et al (1994). Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol, 5, 539-42.
19. Verweij J, Lee SM, Ruka W, et al (2000). Randomized phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol, 18, 2081-6.